Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. Issue 9 (2nd September 2022)

• Record Type: Journal Article
• Authors: Marzolla, Vincenzo; Infante, Marco; Armani, Andrea; Rizzo, Manfredi; Caprio, Massimiliano
• Is Part Of: Expert opinion on drug safety. Volume 21:Issue 9(2022)
• Page Start: 1161
• Page End: 1170
• Publication Date: 2022-09-02
• Subjects: cardiovascular disease -- chronic kidney disease -- diabetic kidney disease -- mineralocorticoid receptor -- type 2 diabetes mellitus; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2022.2130889
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction: Diabetic kidney disease (DKD) represents a leading cause of morbidity and mortality in subjects with diabetes and develops in more than one third of diabetic patients. Steroidal mineralocorticoid receptor antagonists (MRAs – eplerenone and spironolactone) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF). However, in clinical practice the use of steroidal MRAs is limited by the significant risk of hyperkalemia, especially in patients with impaired renal function. Finerenone, a novel nonsteroidal MRA, shows a higher selectivity and binding affinity for mineralocorticoid receptor (MR) compared to steroidal MRAs and has been shown to reduce chronic kidney disease (CKD) progression and cardiovascular mortality in patients with CKD and T2DM. Areas covered: This review summarizes the current evidence on efficacy and safety of finerenone in the treatment of patients with CKD and T2DM, and discusses its mechanisms of action investigated in preclinical studies. Expert opinion: Pharmacological properties of finerenone and its unique tissue distribution are responsible for a lower risk of hyperkalemia. Therefore, finerenone represents a valuable therapeutic tool in patients with CKD/diabetic kidney disease (DKD). Recent studies have shown that finerenone delays the progression of CKD and reduce cardiovascular events in patients with DKD, highlighting its safety and efficacy in this high-risk population.